Vor Biopharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VOR research report →
About the company
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials.
- CEO
- Jean-Paul Kress
- IPO
- 2021
- Employees
- 159
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $141.12M
- P/E
- -0.04
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- -0.06
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 87.31%
- ROIC
- -76.08%
- Revenue
- $0 · 0.00%
- Net Income
- $-695,981,000 · -495.29%
- EPS
- $-70.50 · -107.35%
- Op Income
- $-371,642,000
- FCF YoY
- -43.81%
- 52W High
- $65.80
- 52W Low
- $6.50
- 50D MA
- $15.04
- 200D MA
- $16.99
- Beta
- 1.73
- Avg Volume
- 1.19M
Get TickerSpark's AI analysis on VOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 57,162 |
| Jun 11, 26 | Detheux Michel | other | 57,162 |
| Jun 11, 26 | Namouni Fouad | other | 56,549 |
| Jun 11, 26 | Joustra Wouter | other | 57,162 |
| Jun 11, 26 | Kalir Erez | other | 57,162 |
| Jun 11, 26 | Cumbo Alexander | other | 56,345 |
| Jun 11, 26 | Beckman Daniella | other | 53,283 |
| Jun 11, 26 | Levin Andrew David | other | 57,162 |
| Apr 22, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 165,150 |
| Apr 17, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 458,411 |
Our VOR coverage
Recent articles, reports, and earnings notes.
No research on VOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VOR report →Similar companies
Peers in the same neighborhood.